Human cardiac organoids hold remarkable potential for cardiovascular disease modeling
and human pluripotent stem cell–derived cardiomyocyte (hPSC-CM) transplantation. Here …

The advancement of human induced pluripotent stem-cell-derived cardiomyocyte (hiPSC-
CM) technology has shown promising potential to provide a patient-specific, regenerative …

High-purity cardiomyocytes (CMs) derived from human induced pluripotent stem cells
(hiPSCs) are promising for drug development and myocardial regeneration. However, most …

With the advent of induced pluripotent stem cells and directed differentiation techniques, it is
now feasible to derive individual-specific cardiac cells for human heart tissue engineering …

Recently, carbon nanotubes together with other types of conductive materials have been
used to enhance the viability and function of cardiomyocytes in vitro. Here we demonstrated …

The current inability to derive mature cardiomyocytes from human pluripotent stem cells has
been the limiting step for transitioning this powerful technology into clinical therapies. To …

Engineered cardiac tissues derived from human induced pluripotent stem cells offer unique
opportunities for patient-specific disease modeling, drug discovery and cardiac repair. Since …

Cardiac progenitor cells (CPCs), capable of differentiating into multiple cardiac cell types
including cardiomyocytes (CMs), endothelial cells, and smooth muscle cells, are promising …

Human induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs) offer an
unprecedented opportunity to remuscularize infarcted human hearts. However, studies have …

Human induced pluripotent stem cells (hiPSCs) hold promise for myocardial repair following
injury, but preclinical studies in large animal models are required to determine optimal cell …